These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3571943)

  • 21. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
    Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin-uptake inhibitors in obsessive-compulsive disorder: a case report.
    White K; Keck PE; Lipinski J
    Compr Psychiatry; 1986; 27(3):211-4. PubMed ID: 3458554
    [No Abstract]   [Full Text] [Related]  

  • 23. Severe anorexia and possible psychosis or hypomania after trazodone-tryptophan treatment of aggression.
    Patterson BD; Srisopark MM
    Lancet; 1989 May; 1(8645):1017. PubMed ID: 2565491
    [No Abstract]   [Full Text] [Related]  

  • 24. High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients.
    Weizman A; Carmi M; Hermesh H; Shahar A; Apter A; Tyano S; Rehavi M
    Am J Psychiatry; 1986 Mar; 143(3):335-9. PubMed ID: 3006522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
    Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
    Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obsessive-compulsive disorder and serotonin: is there a connection?
    Insel TR; Mueller EA; Alterman I; Linnoila M; Murphy DL
    Biol Psychiatry; 1985 Nov; 20(11):1174-88. PubMed ID: 2413912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients.
    Zohar J; Kaplan Z; Benjamin J
    J Clin Psychiatry; 1993 Oct; 54(10):385-8. PubMed ID: 7903293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder.
    Markovitz PJ; Stagno SJ; Calabrese JR
    Am J Psychiatry; 1990 Jun; 147(6):798-800. PubMed ID: 2188516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexually dimorphic relationship of a 5-HT2A promoter polymorphism with obsessive-compulsive disorder.
    Enoch MA; Greenberg BD; Murphy DL; Goldman D
    Biol Psychiatry; 2001 Feb; 49(4):385-8. PubMed ID: 11239910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Panic attack precipitated by fluoxetine.
    Saran A; Halaris A
    J Neuropsychiatry Clin Neurosci; 1989; 1(2):219-20. PubMed ID: 2521065
    [No Abstract]   [Full Text] [Related]  

  • 32. Prazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD.
    Feenstra MGP; Klompmakers A; Figee M; Fluitman S; Vulink N; Westenberg HGM; Denys D
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):310-319. PubMed ID: 26712326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls.
    Baxter LR; Phelps ME; Mazziotta JC; Guze BH; Schwartz JM; Selin CE
    Arch Gen Psychiatry; 1987 Mar; 44(3):211-8. PubMed ID: 3493749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports.
    Steiner W; Fontaine R
    Biol Psychiatry; 1986 Sep; 21(11):1067-71. PubMed ID: 3488767
    [No Abstract]   [Full Text] [Related]  

  • 35. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the role of serotonin system genes in obsessive-compulsive disorder.
    Sinopoli VM; Burton CL; Kronenberg S; Arnold PD
    Neurosci Biobehav Rev; 2017 Sep; 80():372-381. PubMed ID: 28576508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination.
    Simeon JG; Thatte S; Wiggins D
    Psychopharmacol Bull; 1990; 26(3):285-90. PubMed ID: 2274627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.